Are early relapses in advanced-stage ovarian cancer doomed to a poor prognosis?

Fabien Vidal, Paul Guerby, Mathieu Luyckx, Pascale Haddad, Eberhard Stoeckle, Philippe Morice, Eric Leblanc, Fabrice Lecuru, Emile Daraï, Jean Marc Classe, Christophe Pomel, Thomas Filleron, Gwenael Ferron, Denis Querleu, Arash Rafii Tabrizi

Research output: Contribution to journalArticle

4 Citations (Scopus)


Objective: Early recurrence (ER) after completion of therapeutic regimen in advanced-stage ovarian cancer is a challenging clinical situation. Patients are perceived as invariably having a poor prognosis.We investigated the possibility of defining different prognostic subgroups and the parameters implicated in prognosis of ER patients. Study Design: We analyzed a multi-centric database of 527 FIGO stage IIIC and IV ovarian cancer patients. We defined patients relapsing within 12 months as ER and investigated using Cox logistic regression the prognostic factors in ER group. We subsequently divided ER patients into good and poor prognosis groups according to a lower or higher overall survival (OS) at 12 months after relapse and determined parameters associated to poor prognosis. Results: The median follow up was 49 months. One hundred and thirty eight patients recurred within 12 months. OS and Disease Free Survival (DFS) were 24.6 and 8.6 months, respectively, in this group of patients. Among the ER patients, 73 had a poor prognosis with an OS after relapse below 12 months (mean OS = 5.2 months) and 65 survived after one year (mean OS = 26.9 months). Residual disease (RD) after debulking surgery and mucinous histological subtype negatively impacted prognosis (HR = 1.758, p = 0.017 and HR = 8.641, p = 0.001 respectively). The relative risk of death within 12 months following relapse in ER patients was 1.61 according to RD status. However, RD did not affect DFS (HR = 0.889, p = 0.5). Conclusion: ER in advanced-stage ovarian cancer does not inevitably portend a short-term poor prognosis. RD status after initial cytoreduction strongly modulates OS, that gives additional support to the concept of maximum surgical effort even in patients who will experience early recurrence. The heterogeneity in outcomes within the ER group suggests a role for tumor biology in addition to classical clinical parameters.

Original languageEnglish
Article numbere0147787
JournalPLoS One
Issue number1
Publication statusPublished - 1 Jan 2016


ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Vidal, F., Guerby, P., Luyckx, M., Haddad, P., Stoeckle, E., Morice, P., Leblanc, E., Lecuru, F., Daraï, E., Classe, J. M., Pomel, C., Filleron, T., Ferron, G., Querleu, D., & Tabrizi, A. R. (2016). Are early relapses in advanced-stage ovarian cancer doomed to a poor prognosis? PLoS One, 11(1), [e0147787].